+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 10Years - 80Years
All Genders
ID07774533

Evaluation of 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Osteosarcoma Patients

Led by Peking University First Hospital · Updated on 2026-08-19

16

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new imaging agent, a 68Ga-labeled B7-H3 nanobody, for immunoPET scans in patients with osteosarcoma, including those with relapsed or refractory disease. The study aims to assess the safety, feasibility, and diagnostic performance of this agent compared to conventional imaging and, when available, tissue analysis. B7-H3 is an immune checkpoint molecule highly present in osteosarcoma tumors but limited in normal tissues, making it a promising target for imaging. Participants will receive a single intravenous dose of the investigational 68Ga-B7-H3 nanobody, followed by PETCT imaging according to the study plan. The study will analyze how the tracer distributes in the body, how much it accumulates in tumors, and its ability to detect lesions. Safety will be monitored by tracking any adverse events related to the tracer. During the study, participants will undergo PETCT scans and safety assessments including monitoring for any side effects within about 30 days after imaging. Imaging results will be compared with standard scans and pathology findings when possible. The primary measures include lesion detection rates and safety outcomes, while secondary measures involve quantifying tracer uptake in osteosarcoma lesions. The study runs from April 2026 to September 2026, with participants aged 10 to 80 years.

CONDITIONS

Brief Title

68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma

Research Team

T

Tingfei Gu, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here